Bexion Pharmaceuticals is a mid-clinical stage biotechnology company developing biologics for the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN). Our lead asset BXQ-350 modulates sphingolipid metabolism, increasing the ratio of certain ceramides to S1P in dysregulated cells, allowing for programmed cell death, reduced proliferation, and immune stimulation. The product has also been shown to potentially prevent and treat CIPN.